Event Participants
Executives
4 Himanshu Muktilal Zota, Ajit Mishra, Moxesh Ketanbhai Zota, Sujit Paul
Analysts
9 Amit Mishra, Arman Nahar, Astha Jain, Chetan Sheth, Dev Jatia, Harsh Shah, Manan Shah, Niharika Agarwal, Randhir Kumar Singh, Swaraj Mehta, Yash Rathi
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue from Operations | ₹17,360 lakhs | Grew 67.6% YoY, driven by network expansion into Dabur India and growth in existing stores |
| Gross Profit | ₹10,756 lakhs | Gross margin improved to 61.96%, reflecting business model strength and product mix |
| Total Store Count | 2,825 stores | Added 264 stores (201 COCO, 63 FOCO); closed 18 (2 COCO, 16 FOCO); net addition of 246 stores |
| Quarterly Footfall | ~60 lakh customers | Increased from ~35 lakh customers in the same quarter last year |
| Total GMV | ₹16,402 lakhs | Highlights increased scale and productivity of retail network |
| COCO Store Sales | ~₹4.13 lakh/store/month | 234 stores from 2021-24 vintage; store-level EBITDA ~15% |
| Marketing Spend (Q1 FY26) | ₹3-4 crores | Compared to current quarter's elevated spend of ₹15-17 crores |
| EBITDA Guidance | Positive by Q1 FY28 | Management guided to EBITDA positive status in Q1 of FY28 |
| Cash Breakeven | Q4 FY27/Q1 FY28 | Within 2-3 quarters, expected to reach cash breakeven or cash positive |
| Full Year Marketing Spend | ₹40-45 crores | Annualizing current spend; will taper from Q1 lumpy levels |
| Rent Expense (Quarterly) | ₹18.5-19 crores | Of total ₹32 crores interest & depreciation; rest is actual depreciation |
| Current Cash Burn | ~₹30 crores | Calculated after adjusting for depreciation of ₹43-44 crores and marketing expense |
Geographic & Segment Commentary
COCO (Company Owned Company Operated) Stores: 1,855 stores as of Q1 FY27. These stores reported average revenue of ₹4.13 lakh per store per month for the 234 stores in the 2021-24 vintage. Store-level EBITDA for this cohort is approximately 15%. Same-store sales growth for COCO stores is tracking at 7.5% QoQ and roughly 30% annually, with mature stores (2+ years) showing stronger performance.
FOCO (Franchise Owned Company Operated) Stores: 970 stores as of Q1 FY27. Added 63 stores during the quarter while closing 16. FOCO stores contribute to total GMV but have a different revenue recognition pattern, resulting in a lower GMV-to-revenue conversion ratio (87% overall vs. 94-95% for COCO stores) due to invoicing methodology differences for franchise operations.
Subsidiary Ventures (YouGo Generic, Skya): Investments of ₹2 crores each made in KMH Ventures Ltd and Curexis Ventures Pvt Ltd during the quarter. Both businesses are in initial rollout/pilot phase with movement expected from next quarter. These ventures are focused on expanding addressable market beyond traditional pharmacy retail.
Company-Specific & Strategic Commentary
Store Expansion Strategy: Added 264 stores in Q1 FY27 (201 COCO, 63 FOCO), bringing network to 2,825 stores. Management intends to moderate expansion pace during Q2 FY27 to focus on improving productivity, monitoring operational trends across recent stores, and strengthening store execution.
Marketing & Brand Building: Elevated marketing spend of ₹15-17 crores in Q1, up from ₹18 crores for full FY26. Spend includes brand ambassador fees for Suniel Shetty and Mahender Singh Dhoni (Dawa India), and Akshay Kumar (Zota Health Care Ltd and subsidiaries). Management guided to ₹40-45 crores for FY27, with Q1 being lumpy due to ambassador tranches and content production costs; BTL activities include camps, roadshows, and community sensitization programs.
IT Infrastructure Investment: Acquired Globotask IT consultancy to build internal IT capability. Strategic rationale includes strengthening data security (keeping all data flow internal across subsidiaries), reducing dependency on external IT vendors, and achieving cost benefits over time.
Rights Issue: Company increased investment in Zota Health Care Ltd through a rights issue during the quarter, reinforcing commitment to scaling India's largest organized private label pharmacy platform.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Store Expansion | Moderated pace in Q2 FY27 | Focus shifts to improving productivity and monitoring trends across recent stores; expansion to resume more aggressively in Q3/Q4 FY27 |
| EBITDA | Positive by Q1 FY28 | Management expects EBITDA positive status in Q1 of FY28 as marketing spend normalizes and mature store base grows |
| Cash Breakeven | Q4 FY27 or Q1 FY28 | Within 2-3 quarters; current cash burn ~₹30 crores per quarter, expected to taper |
| Marketing Spend | ₹40-45 crores for FY27 | Q1 was lumpy (₹15-17 crores) due to ambassador fees tranches and content production; subsequent quarters expected to moderate |
| Gross Margin | Recovery in 2-3 quarters | Q1 gross margin of 61.96% (down 1.5%) expected to return to historical levels as raw material cost pressures from geopolitical issues subside |
| Store Level EBITDA Margin | ~30% after 4 years | Mature stores follow trajectory of 5-7% EBITDA margin improvement per year, reaching ~30% by years 4-5 |
Risks & Constraints
| Risk | Context |
|---|---|
| Marketing Expense Escalation | Marketing spend jumped from ₹18 crores in FY26 to guided ₹40-45 crores in FY27, pressured near-term profitability. Management maintains this is necessary for shifting consumer behavior from branded to generic medicines; analysts have requested separate disclosure of marketing line items for better tracking |
| Margin Deterioration | Gross margin declined 1.5% in Q1 FY27 attributed to geopolitical conflict impacting raw material costs. Management remains confident of recovery within 2-3 quarters but this introduces near-term earnings volatility |
| Execution Risk in Store Expansion | Management has deliberately moderated store addition pace in Q2 FY27 to focus on productivity of 1,000+ stores added in last 2 years. Failure to achieve expected maturity trajectory (30% store-level EBITDA by year 4-5) could impair returns |
| New Subsidiary Uncertainty | YouGo Generic and Skya ventures are in pilot/initial rollout phase with uncertain timelines; investments of ₹2 crores each made this quarter. Additional capital may be required before these achieve scale |
| Competitive Landscape | Jan Aushadhi (~25,000 stores target) and organized players like MedPlus rapidly expanding in the same affordable generic medicine segment. Management emphasizes penetration gap (only ~14,000-15,000 organized retail pharmacies vs. 18-19 lakh total pharmacies) as headroom |
Q&A Highlights
Marketing Expense Rationale
- Question: Why have other expenses increased to 33% of revenue from 21% in Q1 FY26? Will this continue? (Astha Jain)
- Answer: Last year's marketing cost was ~₹18 crores. The company is building awareness for generic medicines in a branded-medicine-driven market. Investment in consumer education and brand building is necessary to shift buying habits. (Sujit Paul)
- Question: Is the ₹15-17 crore quarterly spend annualizing to ₹65-70 crores? (Swaraj Mehta)
- Answer: Marketing will not grow to that level; management is careful with spending. Full year guidance is ₹40-45 crores. Q1 was lumpy due to brand ambassador fees tranches and content production (Sujit Paul).
Store Economics & EBITDA Path
- Question: Can you quantify the gap between mature and new stores (revenue, GP, EBITDA) and time to maturity? (Niharika Agarwal)
- Answer: 234 stores from 2021-24 vintage generate ~₹4.13 lakh per store per month with store-level EBITDA of ~15%. Stores reach maturity in 12-18 months. Same-store sales growth is ~7.5% YoY but roughly 30% annually (Himanshu Zota).
- Question: When can the company turn EBITDA positive? (Arman Nahar, Manan Shah)
- Answer: EBITDA positive expected by Q1 FY28. Cash breakeven within Q4 FY27 or Q1 FY28 (Himanshu Zota).
GMV to Revenue Conversion
- Question: Why did GMV-to-revenue conversion drop to 87% this quarter from 93-94% previously? (Chetan Sheth)
- Answer: The gap is primarily attributable to FOCO stores' different invoicing methodology. COCO stores maintain 94-95% conversion (Himanshu Zota).
Brand Ambassadors & Marketing ROI
- Question: Which ambassadors are appointed for which brands, and how will they be monetized? (Swaraj Mehta)
- Answer: Suniel Shetty and Mahender Singh Dhoni are primarily for Dawa India; Akshay Kumar represents Zota Health Care Ltd and subsidiaries like YouGo Genetic. Management clarified they do not seek to "monetize" ambassadors but build brand awareness (Sujit Paul).
Expansion Moderation Rationale
- Question: Why has management become cautious on expansion despite similar store additions? (Yash Rathi)
- Answer: Q2 FY27 will focus on improving productivity, monitoring operational trends across recently added stores, and strengthening store execution. Expansion will be more aggressive again in Q3 and Q4 FY27 (Moxesh Zota, Himanshu Zota).
Key Takeaway
Zota Health Care delivered a strong Q1 FY27 with revenue from operations growing 67.6% YoY to ₹17,360 lakhs, driven by a net addition of 246 stores (bringing network to 2,825) and same-store sales growth of ~30% annually for mature COCO stores. Gross margin improved to 61.96% but declined 1.5% sequentially due to geopolitical raw material cost pressures, while EBITDA and cash breakeven are guided for Q4 FY27/Q1 FY28. The company is making strategic investments in marketing (₹40-45 crores guided for FY27, with ₹15-17 crores spent in Q1 on brand ambassadors Suniel Shetty, Mahender Singh Dhoni, and Akshay Kumar), IT infrastructure (Globotask acquisition), and subsidiary ventures (YouGo Generic, Skya) to build a diversified healthcare ecosystem. Management intends to moderate store expansion in Q2 FY27 to focus on productivity before resuming aggressive growth, positioning the company to capitalize on India's shift from branded to generic medicines while managing a competitive landscape that includes Jan Aushadhi and other organized players.